We are pleased to share the latest quarterly update on the clinical trial investigating low dose naltrexone (LDN) for people with ME/CFS, funded in part by the ME Association's Ramsay Research Fund, led by Professor Luis Nacul and colleagues in British Columbia, Canada.
Between July and September 2025, the trial saw its most rapid recruitment phase to date:
- 99 eligible pre-screening surveys were received
- 61 new consent discussions were completed
- 50 new participants were formally recruited
- 34 participants began treatment during this period
Cumulatively, the trial has now pre-recruited 208 participants, with 123 dosed and 76 having completed the full trial protocol.
For the MRI sub-study, all first scans for the 50 participants have been completed. Of these, 39 have completed their second scan, marking strong progress toward imaging-based endpoints.
Following the expansion to include Ontario-based participants, the trial is now progressing at its fastest pace since launch. The team continues to work toward full recruitment by the end of October 2025 and remains on track to complete all participant activities by mid-February 2026.
We will continue to share updates as the trial moves into its final stages.
More information
Update: Low-dose naltrexone (LDN) clinical trial: Progress Report April-June 2025 | July 28, 2025
Leading UK Charity invests in Canadian trial of drug treatment for ME/CFS and Long Covid | April 2, 2025